---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-455560"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2026-11-10T21:28:20+00:00"
generated_at: "2026-11-10T21:29:06.000033+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Inhibikase Q3 2026 net loss $20.5M; cash $193.3M to fund IMPROVE-PAH through Part B readout

## Summary
- Q3 2026 net loss $20.5M ($0.10/share) vs $11.9M ($0.13/share) a year earlier; R&D rose to $15.0M from $7.6M and SG&A to $7.2M from $5.6M.
- Cash, cash equivalents and marketable securities were $193.3M at Sept 30, 2026, expected to fund operations through Part B topline, assuming full exercise of Series A and B warrants.
- Phase 3 IMPROVE-PAH has 28 country regulatory approvals and 79 of a planned 180 sites activated; Part A interim safety readout (n=50) planned for first half of 2027.
- July 2026: sold 25,000,000 shares to RA Capital via ATM for $50M gross; 18,030,000 later exchanged for pre-funded warrants. 140.3M shares and 60.6M pre-funded warrants outstanding.
- FDA granted Orphan Drug Designation for IKT-001 in July 2026; board added cardiologist Scott M. Wasserman, MD, CMO of Kailera Therapeutics, in October 2026.

## SEC filing metadata
- accession: 0001193125-26-455560
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2026-11-10T21:28:20+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312526455560/0001193125-26-455560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312526455560/d95716d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-455560
- JSON: https://secwatch.observer/filing/0001193125-26-455560.json
- Plain text: https://secwatch.observer/filing/0001193125-26-455560.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.